Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RYZ801 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| RYZ811 | DIAGNOSTIC_TEST | Ga-68 |
| RYZ801 | DRUG | Ac-225 |
RYZ801 is an investigational small molecule being studied for the treatment of hepatocellular carcinoma (HCC), specifically in subjects with GPC3+ unresectable HCC. It is being evaluated as part of a theranostic pair with RYZ811, a diagnostic agent, to identify and treat patients with this condition.
RYZ801 targets BCMA, a protein. It is being studied in combination with the diagnostic RYZ811 to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC). The therapeutic agent is designed to work alongside the diagnostic to target the disease.
RYZ801 is being developed by Bristol-Myers Squibb Company (ticker: BMY). The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with hepatocellular carcinoma (HCC).
RYZ801 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing trial is recruiting participants to study the theranostic pair RYZ811 and RYZ801 in subjects with GPC3+ unresectable HCC.
RYZ801 is being studied in a Phase 1 clinical trial with the identifier NCT06726161. The trial is titled 'Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable HCC' and is currently recruiting 70 participants.
No, RYZ801 and RYZ811 are different agents. RYZ801 is the therapeutic drug, while RYZ811 is the diagnostic agent. They are studied together as a theranostic pair to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC).